Abstract:Farnesoid X receptor (FXR) is a promising target for drug discovery against nonalcoholic fatty liver disease (NAFLD). However, no FXR agonist has been approved for NAFLD so far. The R & D of FXR agonists are somewhat hindered by the lack of effective and safe chemotypes. To this end, we developed a multi-stage computational workflow to screen the Specs and ChemDiv chemical library for FXR agonists, which consisted of machine learning (ML)-based classifiers, shape-based and electrostatic-based models, a FRED-based molecular docking protocol, an ADMET prediction protocol and substructure search. As a result, we identified a novel chemotype that has never been reported before, with compound XJ02862 (ChemDiv ID: Y020-6413) as the representative. By designing an asymmetric synthesis strategy, we were able to prepare four isomers of compound XJ02862. Interestingly, one of the isomers, 2-((S)-1-((2S,4R)-2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl)-1-oxopropan-2-yl)hexahydro-1H-isoindole-1,3(2H)-dione (XJ02862-S2), showed potent FXR agonistic activity in HEK293T cells. The molecular docking, molecular dynamics simulations and site-directed mutagenesis suggested the hydrogen bond between compound XJ02862-S2 and HIS294 of FXR is essential for ligand binding. We further demonstrated that compound XJ02862-S2 had no agonistic effect on TGR5. Further biological experiments have shown that compound XJ02862-S2 could ameliorate hypercholesterolemia, hepatic steatosis, hyperglycemia, insulin resistance (IR) in high-fat-diet induced obese (DIO) mice. In term of molecular mechanism, compound XJ02862-S2 regulates the expression of FXR downstream genes involved in lipogenesis, cholesterol transport and bile acid biosynthesis and transport. Taken together, we have discovered a novel chemotype as potent FXR agonists for NAFLD by computational modeling, chemical synthesis and biological evaluation.

Structural basis of omega-3 fatty acid receptor FFAR4 activation and G protein coupling selectivity

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Molecular recognition and activation mechanism of short-chain fatty acid receptors FFAR2/3

Structural basis for the ligand recognition and signaling of free fatty acid receptors

Structural insights into endogenous ligand selectivity and activation mechanisms of FFAR1 and FFAR2

Structural insights into ligand recognition and activation of the medium-chain fatty acid-sensing receptor GPR84

Unsaturated bond recognition leads to biased signal in a fatty acid receptor

Label-free Cell Phenotypic Study of FFA4 and FFA1 and Discovery of Novel Agonists of FFA4 from Natural Products.

Structural basis of bile acid receptor activation and Gs coupling

Computational Insights into Molecular Activation and Positive Cooperative Mechanisms of FFAR1 Modulators.

Distinct binding hotspots for natural and synthetic agonists of FFA4 from in silico approaches

A Selectivity Study of FFAR4/FFAR1 Agonists by Molecular Modeling

3D-QSAR and Molecular Dynamics Study of Isoxazole Derivatives to Identify the Structural Requirements for Farnesoid X Receptor (FXR) Agonists

Sensing unsaturated fatty acids: insights from GPR120 signaling

Mechanistic Studies on the Stereoselectivity of FFAR1 Modulators.

FFA4 Receptor (GPR120): A Hot Target for the Development of Anti-Diabetic Therapies.

Characterization of Free Fatty Acid Receptor 4 and Its Involvement in Nutritional Control and Immune Response in Pacific Oysters ( Crassostrea gigas )

Synthesis, Activity, and Docking Study of Novel Phenylthiazole-Carboxamido Acid Derivatives as FFA2 Agonists

A Novel Class of Natural FXR Modulators with a Unique Mode of Selective Co‐regulator Assembly

Discovery of novel FFA4 (GPR120) receptor agonists with β-arrestin2-biased characteristics